Alector (ALEC) Competitors $1.25 -0.12 (-8.76%) Closing price 04:00 PM EasternExtended Trading$1.30 +0.05 (+4.40%) As of 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALEC vs. RLAY, ARVN, ZVRA, UPB, DNA, RGNX, CGEM, SEPN, SAGE, and AMLXShould you be buying Alector stock or one of its competitors? The main competitors of Alector include Relay Therapeutics (RLAY), Arvinas (ARVN), Zevra Therapeutics (ZVRA), Upstream Bio (UPB), Ginkgo Bioworks (DNA), REGENXBIO (RGNX), Cullinan Therapeutics (CGEM), Septerna (SEPN), Sage Therapeutics (SAGE), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. Alector vs. Relay Therapeutics Arvinas Zevra Therapeutics Upstream Bio Ginkgo Bioworks REGENXBIO Cullinan Therapeutics Septerna Sage Therapeutics Amylyx Pharmaceuticals Relay Therapeutics (NASDAQ:RLAY) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, community ranking, valuation, analyst recommendations, dividends, media sentiment, earnings and risk. Is RLAY or ALEC more profitable? Relay Therapeutics has a net margin of 0.00% compared to Alector's net margin of -257.54%. Relay Therapeutics' return on equity of -45.75% beat Alector's return on equity.Company Net Margins Return on Equity Return on Assets Relay TherapeuticsN/A -45.75% -40.75% Alector -257.54%-108.77%-27.03% Does the media prefer RLAY or ALEC? In the previous week, Relay Therapeutics had 2 more articles in the media than Alector. MarketBeat recorded 8 mentions for Relay Therapeutics and 6 mentions for Alector. Relay Therapeutics' average media sentiment score of 1.25 beat Alector's score of 1.16 indicating that Relay Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Relay Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alector 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility & risk, RLAY or ALEC? Relay Therapeutics has a beta of 1.65, meaning that its share price is 65% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500. Do analysts rate RLAY or ALEC? Relay Therapeutics presently has a consensus target price of $17.67, suggesting a potential upside of 517.72%. Alector has a consensus target price of $4.00, suggesting a potential upside of 220.00%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Relay Therapeutics is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relay Therapeutics 0 Sell rating(s) 2 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.83Alector 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14 Which has preferable valuation and earnings, RLAY or ALEC? Alector has higher revenue and earnings than Relay Therapeutics. Relay Therapeutics is trading at a lower price-to-earnings ratio than Alector, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelay Therapeutics$7.68M63.85-$341.97M-$2.23-1.28Alector$88.34M1.41-$130.39M-$1.26-0.99 Do insiders and institutionals have more ownership in RLAY or ALEC? 97.0% of Relay Therapeutics shares are owned by institutional investors. Comparatively, 85.8% of Alector shares are owned by institutional investors. 4.9% of Relay Therapeutics shares are owned by company insiders. Comparatively, 9.1% of Alector shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in RLAY or ALEC? Alector received 94 more outperform votes than Relay Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Relay Therapeutics an outperform vote while only 61.09% of users gave Alector an outperform vote. CompanyUnderperformOutperformRelay TherapeuticsOutperform Votes6370.00% Underperform Votes2730.00% AlectorOutperform Votes15761.09% Underperform Votes10038.91% SummaryRelay Therapeutics beats Alector on 11 of the 18 factors compared between the two stocks. Get Alector News Delivered to You Automatically Sign up to receive the latest news and ratings for ALEC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALEC vs. The Competition Export to ExcelMetricAlectorBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$124.99M$2.93B$5.35B$8.38BDividend YieldN/A1.72%5.22%4.10%P/E Ratio-0.7430.5026.8419.71Price / Sales1.41400.15391.39116.98Price / CashN/A168.6838.2534.62Price / Book0.893.286.794.50Net Income-$130.39M-$72.17M$3.23B$248.18M7 Day Performance16.82%4.28%4.07%1.14%1 Month Performance28.42%7.62%12.52%15.20%1 Year Performance-76.81%-28.15%16.83%6.56% Alector Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALECAlector3.7824 of 5 stars$1.25-8.8%$4.00+220.0%-74.7%$124.99M$88.34M-0.74270News CoveragePositive NewsGap DownRLAYRelay Therapeutics3.3293 of 5 stars$2.81+0.7%$17.67+528.7%-55.0%$481.76M$7.68M-1.08330Positive NewsGap DownARVNArvinas3.7292 of 5 stars$6.49+3.7%$20.92+222.3%-80.0%$473.71M$426.90M-2.34420ZVRAZevra Therapeutics3.2695 of 5 stars$8.66+2.7%$22.29+157.3%+83.6%$473.52M$23.61M-4.4020News CoverageAnalyst RevisionHigh Trading VolumeUPBUpstream Bio2.0917 of 5 stars$8.64-1.6%$56.50+553.9%N/A$464.78M$2.30M0.0038News CoverageDNAGinkgo Bioworks1.1224 of 5 stars$7.92+3.3%$5.77-27.2%N/A$459.75M$237.42M-0.61640Positive NewsRGNXREGENXBIO4.272 of 5 stars$8.89+2.9%$31.63+255.7%-37.0%$445.54M$83.33M-1.77370Analyst RevisionCGEMCullinan Therapeutics2.3232 of 5 stars$7.50+3.6%$32.00+326.7%-67.1%$442.61MN/A-2.6430SEPNSepterna2.0614 of 5 stars$9.84-2.8%$27.00+174.4%N/A$438.04M$1.08M0.00N/AEarnings ReportAnalyst RevisionHigh Trading VolumeSAGESage Therapeutics3.955 of 5 stars$6.89+4.2%$8.81+27.9%-36.2%$431.46M$47.40M-1.05690Analyst DowngradeAMLXAmylyx Pharmaceuticals3.4725 of 5 stars$4.84+7.1%$9.83+103.2%+200.0%$431.44M$-1,272,000.00-1.27200 Related Companies and Tools Related Companies Relay Therapeutics Alternatives Arvinas Alternatives Zevra Therapeutics Alternatives Upstream Bio Alternatives Ginkgo Bioworks Alternatives REGENXBIO Alternatives Cullinan Therapeutics Alternatives Septerna Alternatives Sage Therapeutics Alternatives Amylyx Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALEC) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALEC Stock Free ALEC Stock Alerts